

Supplementary Table S2. Adverse events with durvalumab consolidation

Variable	All grade n, (%)	≥ grade 3 n, (%)
Hyper or hypothyroidism	4 (13.3)	0
Pneumonitis	18 (60)	3 (10)
Liver dysfunction	1 (3.3)	0
Skin disorder	4 (13.3)	0
Arthralgia	3 (10)	0
Eosinophilia	2 (6.7)	0
Creatinine elevation	1 (3.3)	0